DermaSensor
DermaSensor has developed a handheld, FDA-cleared device that utilizes Elastic Scattering Spectroscopy (ESS) combined with Artificial Intelligence (AI) to evaluate skin lesions for cancer risk. This technology allows PCPs to assess suspicious skin lesions in real-time,... Read MoreDermaSensor has developed a handheld, FDA-cleared device that utilizes Elastic Scattering Spectroscopy (ESS) combined with Artificial Intelligence (AI) to evaluate skin lesions for cancer risk. This technology allows PCPs to assess suspicious skin lesions in real-time, providing immediate results that indicate whether a lesion should be monitored or investigated further. Read Less
Builder:
Plugins:
